GSK completes major three-part transaction with Novartis

On March 2, 2015 we completed a 3-part transaction with Novartis which reshapes our business.

We acquired Novartis's vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.

Visit the Global Media Centre to read the press release (note: you will be redirected to the global site. Content available in English only).

Media enquiries 

Corporate Communications +1 905-819-3363 (Mississauga)  
  +1 450-680-4812 (Laval)